Trial Profile
Multicenter phase II trial of doxorubicin and cyclophosphamide (AC) followed by weekly docetaxel (T) as neoadjuvant treatment for operable stage II and IIIA breast cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 20 Sep 2006 New trial record.